Organon & Co. (OGN) research
Organon & Co.- Sector
- Pharmaceuticals
- Last price
- $13.68
- As of
Organon & Co. (OGN): 4 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-07-31.
As of . Source: SEC EDGAR filings for OGN. Method and limitations.
Share the OGN intelligence card
See OGN live in the terminal
Track OGN's insider trades, 13F flows, options positioning, and cross asset confluence as they update, on one live board. Free account.
Open the live OGN terminal, freeActive signals for OGN
- highCONSENSUS_SELL
4 tracked funds reduced OGN this 2026Q2, institutional consensus
- highINSTITUTIONAL_SURGE
MILLENNIUM MANAGEMENT LLC added +1047% to OGN (2026Q2)
- highINSTITUTIONAL_EXIT
CITADEL ADVISORS LLC cut 60% of OGN (2026Q2)
- highINSTITUTIONAL_SURGE
D. E. Shaw & Co., Inc. added +3984% to OGN (2026Q2)
- highINSTITUTIONAL_EXIT
TWO SIGMA INVESTMENTS, LP cut 92% of OGN (2026Q2)
FREE, NO ACCOUNT
Every signal on OGN, as it fires
You are seeing 5 of 23 signals recorded on OGN since 2026-06-03.
The five above landed across 2 days. The other 18 were recorded on 4 other days. 18 of the 23 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in OGN (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| MILLENNIUM MANAGEMENT LLCCUSIP 68622V106 · 2026Q2 | $46.6M | 0.02% | , |
| D. E. Shaw & Co., Inc.CUSIP 68622V106 · 2026Q2 | $9.7M | 0.00% | , |
| CITADEL ADVISORS LLCCUSIP 68622V106 · 2026Q2 | $4.7M | 0.00% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 68622V106 · 2026Q2 | $3.3M | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, OGN
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
OGN against its peers
OGN's net margin of 3.0% ranks in the 69th percentile of 20 Pharmaceuticals sub-industry peers, fiscal periods ending between 2025-12-31 and 2026-06-30.
| Metric | OGN | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 6.2B USD | 638M USD | 93 | 21 |
| Gross margin | 53.3% | 49.5% | 58 | 5 |
| Operating margin | n/a | 4.3% | n/a | 20 |
| Net margin | 3.0% | -2.6% | 69 | 20 |
| Return on equity | 24.9% | -9.3% | 93 | 21 |
| P / E | 19.0x | 15.5x | 55 | 9 |
Peers (25): AMLX, TARS, GPCR, HRMY, SUPN, OCUL, NKTR, BHC, LQDA, AMRX, TRVI, NUVB, ANIP, INVA, XERS, PAHC, OMER, ANRO, AXSM, ALMS, CORT, AMPH, PCRX, JAZZ, ESPR. Fiscal periods ending between 2025-12-31 and 2026-06-30. Every figure is one full fiscal year read from one annual filing (OGN: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
See more OGN signals as they fire
Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to OGNand get the insider, 13F, options, and confluence read in one view.